An interaction study in psoriasis measured drug disposition before and during treatment. Improved inflammation did not automatically produce a meaningful change in midazolam exposure.
Twenty-four patients with moderate-to-severe psoriasis received midazolam assessments before secukinumab and seven and thirty-five days after treatment began. Inflammatory markers declined as expected.
The investigators found no clinically relevant effect on midazolam pharmacokinetics under the tested regimen. Midazolam served as a sensitive CYP3A4 probe rather than a psoriasis treatment.
The open-label design, small sample, disease context, and assessment schedule limit generalization. Other inflammatory disorders, co-medications, or treatment regimens were not all represented.
The study cannot establish that every CYP3A interaction is absent in every patient, nor does it measure driving or cognitive impairment. Forensic interpretation should retain actual dose timing and patient condition. A theoretical cytokine–enzyme mechanism should not be treated as an observed concentration change when this particular clinical experiment did not find one.
Original analysis of the supplied journal article, identified as PMC6896234.